OK BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.95 TWD | +6.35% |
|
+8.81% | +3.39% |
| Sales 2022 | 1.48B 45.54M 62.17M | Sales 2023 | 1.19B 36.59M 49.95M | Capitalization | 3.66B 112M 153M |
|---|---|---|---|---|---|
| Net income 2022 | 143M 4.39M 5.99M | Net income 2023 | 2M 61.39K 83.81K | EV / Sales 2022 | 1.88 x |
| Net Debt 2022 | 144M 4.42M 6.03M | Net cash position 2023 | 33.39M 1.02M 1.4M | EV / Sales 2023 | 3.04 x |
| P/E ratio 2022 |
21.5
x | P/E ratio 2023 |
1,255
x | Employees | - |
| Yield 2022 |
4.46% | Yield 2023 |
1.2% | Free-Float | 75.7% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.35% | ||
| 1 week | +8.81% | ||
| Current month | +5.49% | ||
| 1 month | +8.12% | ||
| 3 months | +4.64% | ||
| 6 months | +7.90% | ||
| Current year | +3.39% |
1 week
23.75
26.25
1 month
23.6526.25
Current year
23.6526.25
1 year
23.6541.37
3 years
19.8741.37
5 years
19.8741.37
10 years
16.7541.37
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Te Lai
CEO | Chief Executive Officer | - | 06-02-28 |
Chi Cheng Hou
DFI | Director of Finance/CFO | - | 10-06-30 |
Te Chyuan Chang
BRD | Director/Board Member | - | 06-02-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chia Te Lai
CEO | Chief Executive Officer | - | 06-02-28 |
Te Chyuan Chang
BRD | Director/Board Member | - | 06-02-02 |
Hsiu Chin Wang
PRN | Corporate Officer/Principal | - | 09-04-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 25.95 | +6.35% | 3,154,184 |
| 24-04-25 | 24.4 | +2.52% | 1,155,711 |
| 24-04-24 | 23.8 | -0.21% | 219,468 |
| 24-04-23 | 23.85 | -0.21% | 286,722 |
| 24-04-22 | 23.9 | +0.21% | 239,680 |
End-of-day quote Taiwan S.E., April 25, 2024
More quotes
OK Biotech Corporation is principally engaged in the manufacture and distribution of medical supplies and products. The Company primarily provides household medical glucose meters and disposable glucose testing strips. Its products are applied in the testing and monitoring of glucose value for diabetes patients, hospitals, clinic doctors and nurses, among others. The Company distributes its products principally in Taiwan, other Asian markets and the United States.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.39% | 116M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.01B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- 4155 Stock
